Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03041766
Recruitment Status : Completed
First Posted : February 3, 2017
Last Update Posted : December 14, 2017
Sponsor:
Collaborators:
Orygen Biotecnologia SA
Biomedical Research Center EPLS
IDRI
Information provided by (Responsible Party):
MIRIAM TENDLER, Oswaldo Cruz Foundation

Brief Summary:
The clinical trial phase 2a is designed to assess the safety of the active ingredient (protein + adjuvant) and secondarily its immunogenicity in healthy male adults from 18 to 49 years of age with a history of infection with intestinal and urinary schistosomiasis, living in the Valley of the Senegal River, a highly endemic area for schistosomiasis. Two arms in the study will test different doses of GLA-SE adjuvant (2.5 and 5 μg). This phase IIA in adults is considered to be a preliminary step in safety before starting trials in children in endemic areas to S. mansoni or S. haematobium, target population of the vaccine.

Condition or disease Intervention/treatment Phase
Schistosomiasis Biological: Sm14 Drug: GLA-SE solution Phase 2

Detailed Description:

A phase 2a trial, self-contained, open-label, randomized, dose-escalation study in two parallel arms receiving three (3) injections at D0, D28, D56; both groups receiving 50 μg Sm14 vaccine candidate solution, either combined with 2.5µg GLA-SE for the first group and 5µg for the second one in adults living in a S. mansoni and S. haematobium endemic area.

Sm14: recombinant protein produced in yeast following Good Manufacturing Practices (GMP) conditions, presented in vials containing 0.55 ml solution Sm14, 0.4 ml solution is diluted with 0.4 ml of GLA (Synthetic Glucopyranosyl lipid A) for intramuscular administration.

Medical examinations are performed at D0 (before injection, 1 hr and 4 hr after), and a safety evaluation at 24 hrs and 48 hrs, after each injection.

Blood analysis: Liver function tests - renal function tests - blood counts, at W-1 before inclusion, and then 7 days after each injections and at W13 and W21 during the follow-up.

Blood samples for immune response analysis at time of each injection, and then W12 and W20.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial
Actual Study Start Date : December 6, 2016
Actual Primary Completion Date : April 6, 2017
Actual Study Completion Date : June 2, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
Biological: Sm14
Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
Other Name: rSm14

Drug: GLA-SE solution
Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
Other Names:
  • Glucopyranosyl Lipid A in Stable Emulsion
  • Glucopyranosyl Lipid Adjuvant-Stable Emulsion
  • Toll-like Receptor 4 Agonist GLA-SE

Experimental: Group 2
Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 5.0 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
Biological: Sm14
Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
Other Name: rSm14

Drug: GLA-SE solution
Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
Other Names:
  • Glucopyranosyl Lipid A in Stable Emulsion
  • Glucopyranosyl Lipid Adjuvant-Stable Emulsion
  • Toll-like Receptor 4 Agonist GLA-SE




Primary Outcome Measures :
  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability. [ Time Frame: within 7 days of the administration of the first dose ]
    . Local signs and symptoms included Pain, Swelling and Inflammation at the injection site, Heaviness or pain upon passive or active movement of the injected limb, Complete physical examination including an examination of general appearance, body weight and forehead temperature, head, eyes, ears, nose and throat, neck, skin, cardiovascular and respiratory system, abdominal system, nervous system, lymphatic area, blood pressure, pulse and respiratory rates. General signs and symptoms including fever, headache, nausea, vomiting, myalgia, arthralgia, irritability/fussiness and drowsiness, loss of appetite and sleep disturbances. Laboratory tests (blood count, liver and kidney biological functions).

  2. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: D30-D37: within 7 days of the administration of the second dose ]
    . Local signs and symptoms included Pain, Swelling and Inflammation at the injection site, Heaviness or pain upon passive or active movement of the injected limb, Complete physical examination including an examination of general appearance, body weight and forehead temperature, head, eyes, ears, nose and throat, neck, skin, cardiovascular and respiratory system, abdominal system, nervous system, lymphatic area, blood pressure, pulse and respiratory rates. General signs and symptoms including fever, headache, nausea, vomiting, myalgia, arthralgia, irritability/fussiness and drowsiness, loss of appetite and sleep disturbances. Laboratory tests (blood count, liver and kidney biological functions).

  3. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: D60-67 : within 7 days of the administration of the third dose ]
    Local signs and symptoms included Pain, Swelling and Inflammation at the injection site. Heaviness or pain upon passive or active movement of the injected limb, Complete physical examination including an examination of general appearance, body weight and forehead temperature, head, eyes, ears, nose and throat, neck, skin, cardiovascular and respiratory system, abdominal system, nervous system, lymphatic area, blood pressure, pulse and respiratory rates. General signs and symptoms including fever, headache, nausea, vomiting, myalgia, arthralgia, irritability/fussiness and drowsiness, loss of appetite and sleep disturbances. Laboratory tests (blood count, liver and kidney biological functions).

  4. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: D90 : three months after the first injection ]
    injection Local signs and symptoms included pain or tenderness, swelling, induration and erythema at the site of injection. Complete physical examination including an examination of general appearance, body weight and forehead temperature, head, eyes, ears, nose and throat, neck, skin, cardiovascular and respiratory system, abdominal system, nervous system, lymphatic area, blood pressure, pulse and respiratory rates. General signs and symptoms including fever, headache, nausea, vomiting, myalgia, arthralgia, irritability/fussiness and drowsiness, loss of appetite and sleep disturbances. Laboratory tests (blood count, liver and kidney biological functions).

  5. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: D120 : four months after the first injection ]
    Local signs and symptoms included pain or tenderness, swelling, induration and erythema at the site of injection. Complete physical examination including an examination of general appearance, body weight and forehead temperature, head, eyes, ears, nose and throat, neck, skin, cardiovascular and respiratory system, abdominal system, nervous system, lymphatic area, blood pressure, pulse and respiratory rates. General signs and symptoms including fever, headache, nausea, vomiting, myalgia, arthralgia, irritability/fussiness and drowsiness, loss of appetite and sleep disturbances. Laboratory tests (blood count, liver and kidney biological functions).


Secondary Outcome Measures :
  1. Qualitative and quantitative assessment of the Immunogenicity [ Time Frame: Day of first administration ]

    Immunogenicity was evaluated by Isotype analysis of the antibodies produced specifically against the rSm14 and vaccine-induced (ELISA) and Specific rSm14 cellular response (on PBMC), production of intracellular cytokines (PBMCs stimulation and cytokine dosing). Cellular immune responses measured by PBMC luminex assay for T-cell cytokines (Milliplex ® MAP kit).

    Correlation between the development and magnitude of humoral responses measured by antibody IgG production to the Sm14 Schisto protein using enzyme-linked immunosorbent assay (ELISA).


  2. Qualitative and quantitative assessment of the Immunogenicity [ Time Frame: 30 days after the first administration ]

    Immunogenicity was evaluated by Isotype analysis of the antibodies produced specifically against the rSm14 and vaccine-induced (ELISA) and Specific rSm14 cellular response (on PBMC), production of intracellular cytokines (PBMCs stimulation and cytokine dosing). Cellular immune responses measured by PBMC luminex assay for T-cell cytokines (Milliplex ® MAP kit).

    Correlation between the development and magnitude of humoral responses measured by antibody IgG production to the Sm14 Schisto protein using enzyme-linked immunosorbent assay (ELISA).


  3. Qualitative and quantitative assessment of the Immunogenicity [ Time Frame: 60 days after the first administration ]

    Immunogenicity was evaluated by Isotype analysis of the antibodies produced specifically against the rSm14 and vaccine-induced (ELISA) and Specific rSm14 cellular response (on PBMC), production of intracellular cytokines (PBMCs stimulation and cytokine dosing). Cellular immune responses measured by PBMC luminex assay for T-cell cytokines (Milliplex ® MAP kit).

    Correlation between the development and magnitude of humoral responses measured by antibody IgG production to the Sm14 Schisto protein using enzyme-linked immunosorbent assay (ELISA).


  4. Qualitative and quantitative assessment of the Immunogenicity [ Time Frame: 90 days after the first administration ]

    Immunogenicity was evaluated by Isotype analysis of the antibodies produced specifically against the rSm14 and vaccine-induced (ELISA) and Specific rSm14 cellular response (on PBMC), production of intracellular cytokines (PBMCs stimulation and cytokine dosing). Cellular immune responses measured by PBMC luminex assay for T-cell cytokines (Milliplex ® MAP kit).

    Correlation between the development and magnitude of humoral responses measured by antibody IgG production to the Sm14 Schisto protein using enzyme-linked immunosorbent assay (ELISA).


  5. Qualitative and quantitative assessment of the Immunogenicity [ Time Frame: 120 days after the first administration ]

    Immunogenicity was evaluated by Isotype analysis of the antibodies produced specifically against the rSm14 and vaccine-induced (ELISA) and Specific rSm14 cellular response (on PBMC), production of intracellular cytokines (PBMCs stimulation and cytokine dosing). Cellular immune responses measured by PBMC luminex assay for T-cell cytokines (Milliplex ® MAP kit).

    Correlation between the development and magnitude of humoral responses measured by antibody IgG production to the Sm14 Schisto protein using enzyme-linked immunosorbent assay (ELISA).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adults, male, 18 to 49 years old (inclusive) at the time of inclusion.
  • Living in one of selected villages in Saint-Louis Region (Senegal).
  • Free of obvious/severe health problems except schistosomiasis, as established by clinical examination and blood analysis, i.e. hematological exams, liver and renal function tests.
  • Written informed consent to participate obtained
  • Treated with 40mg/kg Praziquantel (PZQ) before inclusion (W-5 to W-4 before the first injection) in case of infection with S. mansoni and S. haematobium
  • Residence in the area during the period of the study.

Exclusion Criteria:

  • Adult who does not respond to one of the inclusion criteria
  • Current or previous chronic administration (defined as more than 14 days) of immunosuppressive drugs or other immuno-modifying drugs.
  • Known hypersensitivity to any component in the Sm14 vaccine or history of allergic disease.
  • Knowledge of non-infectious chronic disease
  • Acute disease at time of enrollment.
  • Other conditions which in opinion of the PI may potentially represent a danger for the patient to be enrolled.
  • Non residence in the study area or intent to move during the study period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03041766


Locations
Layout table for location information
Senegal
Biomedical Research Center EPLS
Saint Louis, Senegal, BP226
Sponsors and Collaborators
Oswaldo Cruz Foundation
Orygen Biotecnologia SA
Biomedical Research Center EPLS
IDRI
Investigators
Layout table for investigator information
Study Chair: Miriam Tendler, MD, PhD Oswaldo Cruz Foundation
Principal Investigator: Doudou DIOP, MD Biomedical Research Center ESPOIR POUR LA SANTE (BRC-EPLS)
Study Director: Gilles RIVEAU, PharmD, PhD Biomedical Research Center ESPOIR POUR LA SANTE (BRC-EPLS)

Publications of Results:
Layout table for additonal information
Responsible Party: MIRIAM TENDLER, MD, PhD, Oswaldo Cruz Foundation
ClinicalTrials.gov Identifier: NCT03041766    
Other Study ID Numbers: Sm14-2a-Sn
First Posted: February 3, 2017    Key Record Dates
Last Update Posted: December 14, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by MIRIAM TENDLER, Oswaldo Cruz Foundation:
Schistosomiasis
Recombinant vaccine
rSm14
GLA-SE
Fatty acid-binding protein (FABP)
Phase II Clinical Trial
Senegal
Additional relevant MeSH terms:
Layout table for MeSH terms
Schistosomiasis
Trematode Infections
Helminthiasis
Parasitic Diseases
Vaccines
Pharmaceutical Solutions
Immunologic Factors
Physiological Effects of Drugs